Skip to main content
. 2016 Dec 30;9:31–38. doi: 10.2147/CEOR.S121093

Table 4.

Cost per patient of management of the adverse events (AEs) according to the Monte Carlo simulation

AE severity Erlotinib Afatinib Difference (95% CI)*
AE grade2 €550.86 €980.63 €−429.76
(€−292.48 to −536.40)
AE grade ≥3 €106.58 €291.52 €−184.95
(€−50.08 to −344.89)
All AEs €657.44 €1,272.15 €−614.71
(€−342.57 to −881.29)

Note:

*

The negative values indicate savings with erlotinib versus afatinib.

Abbreviation: CI, confidence interval.